Johnson & Johnson (JNJ) said on Wednesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as a monotherapy for adults with advanced head and neck squamous cell carcinoma.
The designation is supported by data from the Phase 1b/2 OrigAMI-4 study, in which Rybrevant Faspro demonstrated rapid and durable responses in a heavily pretreated patient population.
Rybrevant Faspro is approved in multiple settings for the treatment of non-small cell lung cancer and is also being evaluated in additional solid tumors, including colorectal cancer.
Johnson & Johnson shares closed at $243.33 on Tuesday, down 0.05%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.